3 Beaten Down Stocks Ready to Bounce Back
Not all stocks had a great 2014. Here are three stocks that could be ready for a comeback.
This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year
A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.
This is Incredibly Good News for Breast Cancer Survivors
A recently released study from Canada shines light on the advancements made in treating breast cancer over the past two decades.
Why Inovio Pharmaceuticals Inc. Stock Plunged 15% in November
Inovio Pharmaceuticals stock dips by double-digits in November after the company witnesses a key licensing deal with a major pharmaceutical company come to an end.
This High-Yield Dividend Stock Screams Danger
This high-yield dividend stock may be paying out north of 7%, but its long-term outlook might have investors wisely running in the opposite direction.
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.
3 Drugs That Make Gilead Sciences' Harvoni Look Cheap
Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.
Why Exelixis, Inc. Stock Pushed 11% Higher in October
Exelixis was one of the best biotech stocks in October. Find out what sent its shares higher by 11% and whether or not the good times will keep rolling for this small-cap biotech stock.